Fundraising FoxZylo Therapeutics
Greenville, US · Founded 2017 · Delaware corporation · 5 known investors
Find your way into Zylo Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
107 people can intro you to Charles
Ask Matt Dunbar to introduce you to Charles E. Hinkle
You →Matt · together at Zylo Therapeutics →Charles
91 people can intro you to Scott
Ask Jamie Chen to introduce you to Scott R. Pancoast
You →Jamie · together at San Diego Venture Group →Scott
Sign up to find every way you can get introduced to Zylo Therapeutics
- Your email: who you already know at Zylo Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Zylo Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Zylö Therapeutics develops therapeutic delivery technology, focusing on product development in the biotech and drug-delivery space.
Founders & leadership
Zylo Therapeutics was founded in 2017 by Scott R. Pancoast.
SR
Scott R. PancoastCEO & FounderScott Pancoast is CEO and founder of Zylo Therapeutics, a biotech company developing therapeutic delivery technology. He has prior experience as a venture capitalist and has held multiple CEO and interim CEO roles, as well as board positions at numerous public and private companies.
CE
Charles E. HinkleChief Financial OfficerCharles E. Hinkle is a CPA and Harvard MBA with prior executive experience as CEO and CFO at manufacturing companies, including operations across the USA and Mexico. He has worked on financial and operational improvements using quality systems, lean manufacturing, and continuous improvement methods.
AD
Andrew DraganskiVice President, Product Development
TP
Thomas Patrick MurrayNamed on SEC filing
LM
Lance Michael WhiteNamed on SEC filing
GJ
Gary J AtkinsonNamed on SEC filing
Investors · 5
AEON Foundrylisted by AEON FoundryNew York City
How we know: AEON Foundry's portfolio page · Not right? Tell us
Arieal Southeast Angel Partnerslisted by Arieal Southeast Angel PartnersSavannah · $100K – $2M
How we know: Arieal Southeast Angel Partners's portfolio page · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$4.9M disclosed across 2 of 3 rounds · 2017–2021
▶$1.5MraisedJul 2021 · 12 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedJul 2021 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- LANCE MICHAEL WHITEDirector
- James CordesDirector
- SCOTT RUTLEDGE PANCOASTExecutive Officer, Director
- Matt DunbarDirector
- GARY J. ATKINSONDirector
- Charles E. HinkleExecutive Officer
- Offering amount
- $3.2M
- Amount sold
- $1.5M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$3.4MraisedJun 2019 · 32 investors · PharmaceuticalsRule 506(b)
▶$3.4MraisedJun 2019 · 32 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- LANCE MICHAEL WHITEDirector
- SCOTT RUTLEDGE PANCOASTExecutive Officer, Director
- GARY J. ATKINSONDirector
- MICHAEL ZVI RABINExecutive Officer
- Offering amount
- $4M
- Amount sold
- $3.4M
- Proceeds to insiders
- $513K
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$6MofferedNov 2017 · 4 investors · PharmaceuticalsRule 506(b)
▶$6MofferedNov 2017 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Scott Rutledge PancoastExecutive Officer, Director, Promoter
- Thomas Patrick MurrayExecutive Officer
- Lance Michael WhiteDirector
- Gary J AtkinsonDirector
- Offering amount
- $6M
- Minimum investment
- $10K
- Proceeds to insiders
- $1.4M
- First sale
- Oct 2017
- Incorporated
- Limited Liability Company, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Zylo Therapeutics went on to found or lead other companies.
Related companies · 6
XyloXylo develops mechanism-based drug therapies targeting psychiatric and neurological disorders using computational and rational drug design approaches. The company serves patients and healthcare systems seeking novel treatments for complex neuropsychiatric conditions.
Xilio TherapeuticsXilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment. Its approach aims to achieve durable efficacy for cancer patients while avoiding the severe systemic side effects of conventional immuno-oncology agents.
ZyloZylo provides SaaS and AI spend management software that discovers, tracks, and optimizes enterprise software spending by analyzing financial data and using AI models trained on over $75 billion in transaction data. The platform is designed for enterprise organizations to gain complete visibility and control over their software spend across multiple business units and applications.
SentynlA biopharmaceutical company developing novel medicines for rare diseases, serving patients and caregivers from early detection through therapeutic intervention.
Applied TherapeuticsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Seelos Therapeutics
Companies working in the same space as Zylo Therapeutics.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2023 | $147.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $600K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $263.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Zylo Therapeutics do?
- Zylö Therapeutics develops therapeutic delivery technology, focusing on product development in the biotech and drug-delivery space.
- Who founded Zylo Therapeutics?
- Zylo Therapeutics was founded by Scott R. Pancoast in 2017.
- Who are Zylo Therapeutics's investors?
- Zylo Therapeutics's investors include AEON Foundry, Arieal Southeast Angel Partners, Boston Harbor Angels, Cowtown Angels, HBS Angels of Boston.
- How much funding has Zylo Therapeutics raised?
- Zylo Therapeutics has disclosed $4.9M raised across 2 of its 3 known rounds.
- Where is Zylo Therapeutics headquartered?
- Zylo Therapeutics is headquartered in Greenville, US.